Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. [electronic resource]
Producer: 20040513Description: 252-8 p. digitalISSN:- 0902-4441
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biomarkers, Tumor -- blood
- Bone Resorption -- blood
- Cyclophosphamide -- administration & dosage
- Dexamethasone -- administration & dosage
- Diphosphonates -- therapeutic use
- Doxorubicin -- administration & dosage
- Female
- Fibroblast Growth Factor 2 -- blood
- Follow-Up Studies
- Glycoproteins -- blood
- Humans
- Life Tables
- Male
- Melphalan -- administration & dosage
- Membrane Glycoproteins -- blood
- Middle Aged
- Multiple Myeloma -- blood
- Neoplasm Proteins -- blood
- Neoplasm Staging
- Neovascularization, Pathologic -- blood
- Osteoprotegerin
- Pamidronate
- Prednisone -- administration & dosage
- Prognosis
- Proteoglycans -- blood
- Receptors, Cytoplasmic and Nuclear -- blood
- Receptors, Tumor Necrosis Factor
- Survival Analysis
- Syndecan-1
- Syndecans
- Vincristine -- administration & dosage
- beta 2-Microglobulin -- analysis
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.